Results 81 to 90 of about 25,852 (233)

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

P2Y12 expression and function in alternatively activated human microglia [PDF]

, 2015
Objective: To investigate and measure the functional significance of altered P2Y12 expression in the context of human microglia activation. Methods: We performed in vitro and in situ experiments to measure how P2Y12 expression can influence disease ...
Moore, Craig S., Butovsky, Oleg, Rao, Vijayaraghava T.S., Bar-Or, Amit, Kinsara, Angham, Michell-Robinson, Mackenzie, Leong, Soo Yuen, Ludwin, Samuel K., Séguéla, Philippe, Ase, Ariel R., Antel, Jack P.   +10 more
core   +1 more source

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

The effect of P2Y12 inhibition on platelet activation assessed with aggregation- and flow cytometry-based assays

Platelets, 2017
Patients on P2Y12 inhibitors may still develop thrombosis or bleeding complications. Tailored antiplatelet therapy, based on platelet reactivity testing, might reduce these complications.
Tesse C. Leunissen, Peter Paul Wisman, Thijs C. van Holten, Philip G. de Groot, Suzanne J. Korporaal, Arnold C. Koekman, Frans L. Moll, Martin Teraa, Marianne C. Verhaar, Gert Jan de Borst, Rolf T. Urbanus, Mark Roest   +11 more
doaj   +1 more source

The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration

Platelets, 2022
Here, we report the in vitro characterization of the P2Y12 receptor antagonist selatogrel (ACT-246475). Binding studies with radiolabeled selatogrel demonstrated that selatogrel is a competitive antagonist of ADP binding to the P2Y12 receptor with a fast
Martine Baumann, Benoît Lack, Isabelle Guillaumat, Mark J. Murphy, Markus A. Riederer   +4 more
doaj   +1 more source

Metal‐dependent regulated cell death: Molecular architecture and translational frontiers

iMeta, EarlyView.
Intracellular metal dyshomeostasis orchestrates distinct regulated cell death programs, including iron‐driven ferroptosis, copper‐mediated cuproptosis, calcicoptosis, newly designated zincoptosis, mnoptosis, and coptosis. This review systematically delineates their molecular architectures—spanning from Sorafenib‐induced lipid peroxidation and ...
Haoliang Hu, Zhe Chen, Yaqi Li, Jiayi Peng, Jiangang Cao, Hong Zhou, Mengqi Wang, Yuejia Du, Hailin Wu, Huiqin Zhao, Shifang Huang, Dianmei Yu, Meiqing Liu, Olga V. Shevchenko, Natalia Yu. Matveeva, Yiyuan Yang, Kerui Huang, Deguan Lv, Junxia Min, Linxi Chen, Fudi Wang   +20 more
wiley   +1 more source

Evaluating the impact of a newly established hospitalist medicine procedure service on length of stay and procedural outcomes: A retrospective propensity‐matched analysis

Journal of Hospital Medicine, EarlyView.
Abstract Background Reliance on interventional radiology (IR) has been associated with delays in procedure completion and prolonged hospital length of stay (LOS). Hospitalist medicine procedure services (HMPS) have been proposed as a strategy to mitigate these inefficiencies, though outcomes of newly established programs composed of physicians with ...
Jeremy Gentile, Saria Alazmeh, Kriti Soni, Tarek Alsibai, Felicia Wright, Alicia Stowe, Fergus Peacock   +6 more
wiley   +1 more source

Bioactive Natural Products in Cardiovascular Disease: Focus on Thrombotic Events

Phytotherapy Research, EarlyView.
An overview of the role of natural products (NP) in cardiovascular disease prevention, highlighting key mechanisms of action: including antiplatelet, antithrombotic, anti‐inflammatory, and antioxidant effects. Additionally, it illustrates the integration of diet–drug interactions, nutritional epigenetics, and the role of artificial intelligence in ...
Maria Nektaria Magkoulia, Despoina Pantazi   +1 more
wiley   +1 more source

Inhibiting the P2Y12 Receptor in Megakaryocytes and Platelets Suppresses Interferon-Associated Responses

JACC: Basic to Translational Science
Summary: The authors investigated the impact of antiplatelet therapy on the megakaryocyte (MK) and platelet transcriptome. RNA-sequencing was performed on MKs treated with aspirin or P2Y12 inhibitor, platelets from healthy volunteers receiving aspirin or
Marcin A. Sowa, PhD, Haoyu Sun, PhD, Tricia T. Wang, BA, Vitor W. Virginio, PhD, Florencia Schlamp, PhD, Hanane El Bannoudi, PhD, MacIntosh Cornwell, PhD, Hannah Bash, BA, Peter M. Izmirly, MD, H. Michael Belmont, MD, Kelly V. Ruggles, PhD, Jill P. Buyon, MD, Deepak Voora, MD, Tessa J. Barrett, PhD, Jeffrey S. Berger, MD   +14 more
doaj   +1 more source

Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring

Frontiers in Pharmacology, 2017
Aims: Dual platelet inhibition using anti-P2Y12 drugs and aspirin is the standard of care in patients after percutaneous coronary interventions (PCI). Prasugrel and ticagrelor have been shown to be more potent than clopidogrel with less high on-treatment
Valentina Forni Ogna, Isabelle Bassi, Isabelle Menetrey, Olivier Muller, Eric Tousset, Pierre Fontana, Pierre Fontana, Eric Eeckhout, Chin B. Eap, Chin B. Eap, Bernard Vrijens, Michel Burnier, Grégoire Wuerzner   +12 more
doaj   +1 more source